Aldeyra Therapeutics, Inc.

Name: Aldeyra Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

ALDXNasdaqCIK 1341235HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$5.9m, Q2 FY2026

Net income−$5.5m, Q2 FY2026

Aldeyra Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$m	7.0	4.3	6.2	15.0	12.4	14.6	7.4	8.5	5.4	4.3	2.4	3.5
Operating income	$m	(9.6)	(6.1)	(9.4)	(18.0)	(16.1)	(16.6)	(10.4)	(10.2)	(8.0)	(6.7)	(3.5)	(5.9)
Interest expense	$m	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.0
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(8.2)	(4.8)	(8.1)	(16.8)	(15.1)	(15.8)	(9.9)	(9.8)	(7.7)	(6.5)	(3.5)	(5.5)
Diluted EPS	$ per share	(0.14)	not reported	(0.14)	(0.28)	(0.25)	not reported	(0.17)	(0.16)	(0.13)	not reported	(0.06)	(0.09)
Basic EPS	$ per share	(0.14)	not reported	(0.14)	(0.28)	(0.25)	not reported	(0.17)	(0.16)	(0.13)	not reported	(0.06)	(0.09)

Balance sheet

Cash and equivalents$70.0m, FY2025

Long-term debt$0, Q1 FY2026

Shareholders' equity$37.9m, Q2 FY2026

Aldeyra Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	not reported	not reported	102	71.0	68.1	54.5	50.4	41.2	59.3	70.0	not reported	not reported
Current assets	$m	147	148	141	126	117	104	92.7	84.6	77.5	71.8	66.3	47.4
Total assets	$m	147	148	141	126	117	105	93.2	85.0	77.8	72.1	66.5	47.5
Current liabilities	$m	21.6	22.3	21.7	27.6	17.2	18.6	14.3	29.5	28.5	27.8	24.3	9.7
Total liabilities	$m	24.3	28.5	27.9	27.7	32.2	33.6	29.6	29.7	28.6	27.8	24.3	9.7
Long-term debt	$m	2.7	0.0	0.0	0.0	15.0	15.0	15.1	0.0	0.0	0.0	0.0	not reported
Current portion of debt	$m	13.5	15.1	15.2	15.2	0.3	0.0	0.0	15.1	15.2	15.2	15.3	0.0
Shareholders' equity	$m	123	120	113	98.3	85.1	71.0	63.6	55.3	49.2	44.3	42.2	37.9

Cash flow

Operating cash flow−$4.6m, Q2 FY2026

Capital expenditure$0, Q4 FY2023

Aldeyra Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(8.0)	0.5	(10.0)	(13.2)	(8.0)	(12.0)	(12.5)	(8.6)	(7.0)	(5.3)	(5.1)	(4.6)
Capital expenditure	$m	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)60.32m, Q2 FY2026

Aldeyra Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	58.5	58.8	58.8	59.0	59.4	59.4	59.5	59.9	60.0	60.1	60.3	60.3

Shares outstanding: 60.33m at Aug 4, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. Listed shows no prices and gives no investment advice.